Skip to main content

Advertisement

Log in

Efficacy of oral moxifloxacin for aerobic vaginitis

  • Original Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

The purpose of this study was to investigate the therapeutic efficacy of oral moxifloxacin for aerobic vaginitis (AV). We also identified factors that are associated with therapeutic efficacy. This prospective study enrolled general gynecological outpatients at Tianjin Medical University General Hospital between September 2012 and May 2014. Women diagnosed with AV (n = 102) were recruited. All enrolled women were treated with oral moxifloxacin, 400 mg once daily for 6 days (one course). Therapeutic efficacy was evaluated based on microscopic criteria, and cure rates were calculated. Women who were microscopically improved (but not cured) received a second course of therapy. Women classified with microscopic failure were treated using other strategies. Univariate and multivariate logistic regression analysis was used to identify factors that may be associated with a cure after one course of therapy. After one course of therapy, 65.7 % (67/102) of women were cured, 29.4 % (30/102) of women were improved (but not cured), 4.9 % (5/102) of women failed to respond to the therapy. After two courses of therapy, 85.3 % (87/102) of women were cured, 9.8 % (10/102) of women were improved, 4.9 % (5/102) of women failed to respond to the therapy, and clinical improvement was achieved in additional women. In the multivariate logistic regression analysis, women with a baseline vaginal pH value of <5.0 had a 3.5-times higher chance of being cured, compared with those with a baseline vaginal pH value of ≥5.0 (OR, 3.503; 95 % CI, 1.278–9.601). Moxifloxacin is an effective therapeutic option for patients with AV. Most women with AV were cured with one course of moxifloxacin. For those with a higher vaginal pH value of ≥5.0 before treatment, two courses of therapy should be considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Donders GG, Vereecken A, Bosmans E, Dekeersmaecker A, Salembier G, Spitz B (2002) Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. BJOG 109(1):34–43

    Article  PubMed  Google Scholar 

  2. Tansarli GS, Kostaras EK, Athanasiou S, Falagas ME (2013) Prevalence and treatment of aerobic vaginitis among non-pregnant women: evaluation of the evidence for an underestimated clinical entity. Eur J Clin Microbiol Infect Dis 32(8):977–984

    Article  PubMed  CAS  Google Scholar 

  3. Donders G, De Wet HG, Hooft P, Desmyter J (1993) Lactobacilli in Papanicolaou smears, genital infections, and pregnancy. Am J Perinatol 10(5):358–361

    Article  PubMed  CAS  Google Scholar 

  4. Marconi C, Donders GG, Martin LF, Ramos BR, Duarte MT, Parada CM, Tristão AR, Silva MG (2012) Chlamydial infection in a high risk population: association with vaginal flora patterns. Arch Gynecol Obstet 285(4):1013–1018

    Article  PubMed  Google Scholar 

  5. Donders G, Bellen G, Rezeberga D (2011) Aerobic vaginitis in pregnancy. BJOG 118(10):1163–1170

    Article  PubMed  Google Scholar 

  6. Tempera G, Abbadessa G, Bonfiglio G, Cammarata E, Cianci A, Corsello S, Raimondi A, Ettore G, Nicolosi D, Furneri PM (2006) Topical kanamycin: an effective therapeutic option in aerobic vaginitis. J Chemother 18(4):409–414

    Article  PubMed  CAS  Google Scholar 

  7. Sobel JD (1994) Desquamative inflammatory vaginitis: a new subgroup of purulent vaginitis responsive to topical 2% clindamycin therapy. Am J Obstet Gynecol 171(5):1215–1220

    Article  PubMed  CAS  Google Scholar 

  8. Fan A, Yue Y, Geng N, Zhang H, Wang Y, Xue F (2013) Aerobic vaginitis and mixed infections: comparison of clinical and laboratory findings. Arch Gynecol Obstet 287(2):329–335

    Article  PubMed  Google Scholar 

  9. Nugent RP, Krohn MA, Hillier SL (1991) Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 29(2):297–301

    PubMed  CAS  PubMed Central  Google Scholar 

  10. Aroutcheva A, Gariti D, Simon M, Shott S, Faro J, Simoes JA, Gurguis A, Faro S (2001) Defense factors of vaginal lactobacilli. Am J Obstet Gynecol 185(2):375–379

    Article  PubMed  CAS  Google Scholar 

  11. Dover SE, Aroutcheva AA, Faro S, Chikindas ML (2008) Natural antimicrobials and their role in vaginal health: a short review. Int J Probiotics Prebiotics 3(4):219–230

    PubMed  PubMed Central  Google Scholar 

  12. Hooper DC, Wolfson JS (1991) Fluoroquinolone antimicrobial agents. N Engl J Med 324(6):384–394

    Article  PubMed  CAS  Google Scholar 

  13. Tempera G, Furneri PM (2010) Management of aerobic vaginitis. Gynecol Obstet Invest 70(4):244–249

    Article  PubMed  Google Scholar 

  14. Choi SY, Chang CE, Kim SC, So JS (2003) Antimicrobial susceptibility and strain prevalence of Korean vaginal Lactobacillus spp. Anaerobe 9(6):277–280

    Article  PubMed  CAS  Google Scholar 

  15. Guay DR (2006) Moxifloxacin in the treatment of skin and skin structure infections. Ther Clin Risk Manag 2(4):417–434

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Soussy CJ, Nguyen J, Goldstein F, Dabernat H, Andremont A, Leclercq R, Drugeon H, Cavallo P, Chardon H, Etienne J, Rio Y, Courvalin P (2003) In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study. Clin Microbiol Infect 9(10):997–1005

    Article  PubMed  CAS  Google Scholar 

  17. Sobottka I, Wegscheider K, Balzer L, Böger RH, Hallier O, Giersdorf I, Streichert T, Haddad M, Platzer U, Cachovan G (2012) Microbiological analysis of a prospective, randomized, double-blind trial comparing moxifloxacin and clindamycin in the treatment of odontogenic infiltrates and abscesses. Antimicrob Agents Chemother 56(5):2565–2569

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  18. Tempera G, Bonfiglio G, Cammarata E, Corsello S, Cianci A (2004) Microbiological/clinical characteristics and validation of topical therapy with kanamycin in aerobic vaginitis: a pilot study. Int J Antimicrob Agents 24(1):85–88

    Article  PubMed  CAS  Google Scholar 

  19. Speciale A, Musumeci R, Blandino G, Milazzo I, Caccamo F, Nicoletti G (2002) Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates. Int J Antimicrob Agents 19(2):111–118

    Article  PubMed  CAS  Google Scholar 

  20. Nicolau DP (2001) Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection 29(Suppl 2):11–15

    PubMed  CAS  Google Scholar 

  21. Thomas J, Linton S, Corum L, Slone W, Okel T, Percival SL (2012) The affect of pH and bacterial phenotypic state on antibiotic efficacy. Int Wound J 9(4):428–435

    Article  PubMed  Google Scholar 

  22. Yang L, Wang K, Li H, Denstedt JD, Cadieux PA (2014) The influence of urinary ph on antibiotic efficacy against bacterial uropathogens. Urology 84(3):731

    Article  PubMed  Google Scholar 

  23. Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R (2004) Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 26(7):940–950

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by the National Natural Science Fund of China (No. 81471419) and partially supported by grants from the Science Fund of Tianjin Medical University (No. 2013ky01).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to F. Xue.

Ethics declarations

All authors have read and have abided by the statement of ethical standards for manuscripts submitted to “European Journal of Clinical Microbiology & Infectious Diseases”. The study was reviewed and approved by the ethical committee of Tianjin Medical University General Hospital, and the participants were enrolled into the study after obtaining their written informed consent.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, C., Han, C., Geng, N. et al. Efficacy of oral moxifloxacin for aerobic vaginitis. Eur J Clin Microbiol Infect Dis 35, 95–101 (2016). https://doi.org/10.1007/s10096-015-2513-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-015-2513-8

Keywords

Navigation